,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2010', 'fs': 'Nov 2010', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywA2AQ'}, 'Id': 'a0POZ000000qywA2AQ', 'Event_Date__c': '2010-11-26', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Nov 2010', 'Status_History__c': 'a132P000000AphMQAS'}, 'change': None}]",Nov 2010,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2010', 'fs': 'Dec 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywB2AQ'}, 'Id': 'a0POZ000000qywB2AQ', 'Event_Date__c': '2010-12-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2010', 'Status_History__c': 'a132P000000AphSQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2011', 'fs': 'Feb 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywC2AQ'}, 'Id': 'a0POZ000000qywC2AQ', 'Event_Date__c': '2011-02-17', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Feb 2011', 'Status_History__c': 'a132P000000ApmrQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2011', 'fs': 'Apr 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 15 April 2011.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 15 April 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywD2AQ'}, 'Id': 'a0POZ000000qywD2AQ', 'Event_Date__c': '2011-04-15', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 15 April 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Apr 2011', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ApoSQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2011', 'fs': 'Aug 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywE2AQ'}, 'Id': 'a0POZ000000qywE2AQ', 'Event_Date__c': '2011-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2011', 'Status_History__c': 'a132P000000AprhQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2011', 'fs': 'Aug 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywF2AQ'}, 'Id': 'a0POZ000000qywF2AQ', 'Event_Date__c': '2011-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2011', 'Status_History__c': 'a132P000000ApsQQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-08.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-08.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2011', 'fs': 'Aug 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 26 August 2011.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 26 August 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywG2AQ'}, 'Id': 'a0POZ000000qywG2AQ', 'Event_Date__c': '2011-08-26', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 26 August 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-08.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2011', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ApshQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2011', 'fs': 'Nov 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywH2AQ'}, 'Id': 'a0POZ000000qywH2AQ', 'Event_Date__c': '2011-11-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2011', 'Status_History__c': 'a132P000000ApwEQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2022', 'fs': 'Jun 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywL2AQ'}, 'Id': 'a0POZ000000qywL2AQ', 'Event_Date__c': '2022-06-24', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2022', 'Status_History__c': 'a132P000000ECilQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 28 October 2022', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 28 October 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywM2AQ'}, 'Id': 'a0POZ000000qywM2AQ', 'Event_Date__c': '2022-09-30', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 28 October 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000ECjEQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that trastuzumab for the treatment of locally advanced or metastatic gastric cancer be listed with a <strong>high priority</strong> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application</strong><span style=""font-size: 9pt;""> — (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for application meeting the following criteria: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has locally advanced or metastatic gastric cancer expressing HER-2 IHC 2+FISH+ or IHC3+; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG score of 0-2.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">— (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Trastuzumab to be discontinued at disease progression.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee noted the high health needs relating to the significant symptom burden and modest survival from gastric cancer, the apparent survival advantage from treatment with trastuzumab and likely reduced health resource usage, and the significant cost impact of use of biosimilar trastuzumab in this indication, and the likely reduction in price of trastuzumab following the current competitive process.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that trastuzumab for the treatment of locally advanced or metastatic gastric cancer be listed with a <strong>high priority</strong> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application</strong><span style=""font-size: 9pt;""> — (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for application meeting the following criteria: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has locally advanced or metastatic gastric cancer expressing HER-2 IHC 2+FISH+ or IHC3+; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG score of 0-2.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">— (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Trastuzumab to be discontinued at disease progression.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee noted the high health needs relating to the significant symptom burden and modest survival from gastric cancer, the apparent survival advantage from treatment with trastuzumab and likely reduced health resource usage, and the significant cost impact of use of biosimilar trastuzumab in this indication, and the likely reduction in price of trastuzumab following the current competitive process.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding trastuzumab for the treatment of gastric cancer on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experience a significantly higher rate of stomach cancer than non-Māori<span style=""font-size: 10pt;""> </span>and that Māori also experience a significantly higher mortality rate from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a><u>). </u></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for trastuzumab for the treatment of HER2-positive gastric cancer was reviewed by <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"">PTAC</a> (recommended for funding with a low priority) and the <a href=""https://pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf"" target=""_blank"">Cancer Treatments Advisory Committee</a> (at the time “CaTSoP”, recommended for decline) in 2011. The Committee noted that, in 2011, the clinical relevance of the survival benefits seen in the pivotal ToGa trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/20728210/"" target=""_blank"">Bang et al. Lancet. 2010;376:687-97</a>) were unclear. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that since 2011, more evidence has become available for the use of trastuzumab in the treatment of gastric cancer. The Committee also noted that, at a CTAC meeting in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, the Committee supported a competitive process for the supply of trastuzumab, and considered that further assessment of the use of trastuzumab in gastric cancer was warranted.</p><h3><em>Health Need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to the <a href=""https://www.health.govt.nz/publication/new-cancer-registrations-2018"" target=""_blank"">2018 new cancer registration data from the Ministry of Health</a> (Manatū Hauora), stomach cancer occurs at a rate of 5.3 per 100,000 in New Zealand, with the total number of registrations at 408 for that year. The Committee also noted that mortality data from 2017 indicates that 288 New Zealanders died from stomach cancer that year, 47 of which were Māori. The Committee also noted that a further 90 New Zealanders likely died from cancer of the gastro-oesophageal junction in that year. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to Ministry of Health New Zealand Cancer Registry data, in 2021 85 of the total 500 stomach cancer registrations were Māori, and 48 were of Pacific ethnicity. The Committee noted that data from Qlik also reports that, for “lower third oesophageal cancer registrations”, 19 registrations out of a total of 183 were for individuals who were of Māori ethnicity and 3 were of Pacific ethnicity. The Committee considered that it was reasonable to assume that all cancer registrations for the lower third of the oesophagus would be considered part of the gastro-oesophageal junction and therefore eligible for treatment with trastuzumab. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that globally the vast majority of gastric cancers are adenocarcinomas, which can be further subdivided into intestinal and diffuse type, with intestinal-type gastric cancer being more common in older individuals and more strongly associated with exposure to environmental risk factors. The Committee noted that diffuse-type gastric cancer is more associated with an earlier onset and a family history of the disease. The Committee also noted that HER2-positivity is predominantly seen in intestinal type gastric cancer, with a low prevalence in diffuse type gastric cancer (32% vs. 6%; <a href=""https://pubmed.ncbi.nlm.nih.gov/18441328/"" target=""_blank"">Gravalos C. Jimeno A. Ann Oncol. 2008;19:1523-9</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Although the rate of stomach cancer for both Māori and non-Māori has nearly halved over the last 20 years, the Committee noted that compared with non-Māori, Māori experience significantly higher rates of both stomach cancer incidence and mortality from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a>). The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pacific peoples also experience higher rates of both incidence and mortality in relation stomach cancer compared with New Zealand Europeans. The Committee noted that in addition to genetic factors, Māori and Pacific peoples’ have an increased exposure to environmental risk factors for gastric cancer, and their health outcomes from gastric cancer are further compromised by the late stage of the cancer at diagnosis, limited access to endoscopy services outside of main centres.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the initial symptoms of gastric cancer are often non-specific, and that progressive gastric cancers lead to nutritional decline, difficulty swallowing, and a rapidly declining performance status. The Committee also noted that gastric cancer is associated with a high level of carer burden. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that currently, treatment options for gastric cancer in New Zealand are limited, with those affected generally receiving doublet chemotherapy, with response rates at about 50%, and a duration of response limited to six-nine months. The Committee noted that generally individuals are usually only able to be treated with one line of treatment and/or palliative care. The Committee noted that in New Zealand treatment would be either Xelox (capecitabine and oxaliplatin) or FOLFOX (folinic acid, fluorouracil, and oxaliplatin). The Committee considered that use of triplet chemotherapy is generally rare (owing to increased toxicity with marginal incremental benefit), and that very few would have triplet chemotherapy in New Zealand.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that internationally, treatment of gastric cancer is often driven by biomarker status (eg HER-2, dMMR +/-, PD-L1 status). </p><h3><em>Health Benefit</em></h3><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that trastuzumab is a monoclonal antibody that targets the HER2 receptor, inducing antibody-dependent cellular cytotoxicity, inhibiting HER2-mediated signalling, and preventing cleavage of the extracellular domain of HER2. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted again the primary trial for trastuzumab in combination with chemotherapy compared with chemotherapy alone in the treatment of gastric cancer (ToGa trial) which recruited 594 patients with inoperable, locally advanced, recurrent, and/or metastatic HER2-positive cancer of the stomach or the gastro-oesophageal junction. The Committee noted that the median overall survival for the total trial population was 13.8 months with trastuzumab compared to 11.1 months for those treated with chemotherapy alone (hazard ratio [HR] 0.74; 95% CI 0.60 to 0.91; p=0.0046). The Committee noted that for patients with high HER2 expression (IHC 2+ and FISH-positive tumours or IHC 3+ tumours) the median overall survival was 16.0 months with trastuzumab treatment, versus 11.8 months with chemotherapy alone (HR 0.65; 95% CI 0.51 to 0.83). The Committee noted that the benefit of trastuzumab treatment is greater for patients with higher HER2 expression, with the greatest benefit seen in those with IHC 3+/FISH positive patients. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the addition of trastuzumab to cisplatin and 5FU-based therapy increased response rates from 35% to 47%. The Committee also noted that the toxicities were similar between treatment arms, with a minor increase in grade 3-4 diarrhoea and asymptomatic reduction in left ventricular ejection fraction with trastuzumab. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the following additional evidence for the use of trastuzumab in the treatment of gastric cancer: </p><p class=""ql-indent-1"">1.16.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26857702/"" target=""_blank"">Gong et al. MBC Cancer. 2016;16:68</a> CGOG 1001: an open-label, multicenter, prospective phase II study (n=51) of trastuzumab in combination of oxaliplatin and capecitabine in which 66.5%of participants responded to treatment. </p><p class=""ql-indent-1"">1.16.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784321/pdf/nihms-1051900.pdf"" target=""_blank"">Mondaca et al. Gastric Cancer. 2019;22:355-62</a>: a single-arm multicentre phase II study (n=26) of trastuzumab in combination with docetaxel and 5-flurouracil in which the objective response rate was 65%, and the toxicity profile was high. </p><p class=""ql-indent-1"">1.16.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30927036/"" target=""_blank"">Rivera et al. Cancer Chemother Pharmacol. 2019;83:1175-81</a> HERXO: a multicentre, prospective, non-randomised, non-controlled, open-label national (Spanish) phase II study (n=45) of trastuzumab in combination with oxaliplatin and capecitabine which reported a 46.7% response rate. </p><p class=""ql-indent-1"">1.16.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31768696/"" target=""_blank"">Yuki et al. Cancer Chemother Pharmacol. 2020;85:217-23</a> SOX: a multicentre, open-label, single arm, phase II trial (n=39) of trastuzumab in combination with oxaliplatin and S-1 which reported an 82.1% response rate. </p><p class=""ql-indent-1"">1.16.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31102009/"" target=""_blank"">Takahari et al. Gastric Cancer. 2019;22:1238-46</a>: a multicentre, prospective, single-arm phase II study (n=75) of trastuzumab in combination with oxaliplatin and S-1 which reported an objective response rate of 70.7%. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted a meta-analysis comparing the chemotherapy backbones for first-line trastuzumab treatment-containing regimens for HER2-postive advanced oesophagogastric cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/29451302/"" target=""_blank"">Ter Veer et al. Int J Cancer. 2018;143:438-48</a>) which reported an overall survival advantage with oxaliplatin versus cisplatin (20.7 months versus 16 months, respectively; HR 0.75). The Committee noted that oxaliplatin regimens are also less toxic than cisplatin regimens. The Committee considered that the difference in overall survival in the meta-analysis compared to the ToGa trial is likely due to the improvement in best supportive care since publication of the ToGa trial. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence indicates an advantage for an oxaliplatin doublet, such as Xelox or FLOFOX, rather than the ToGa regimen of cisplatin with 5-FU. The Committee considered that triplet regimens show no additional survival benefit and have worse toxicity profiles. </p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that if trastuzumab were to be funded in this setting, there would be a slight decrease in demand on family support and palliative care services. The Committee considered that those who progress following treatment with a trastuzumab containing regimen in the first line, would then be treated with a taxane chemotherapy. </p><h3><em>Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that use of trastuzumab in this setting would add an additional 30 minutes to an already prolonged chemotherapy administration regimen but considered that this would not impact the number of people with gastric cancer receiving treatment in this setting. The Committee noted that there was no evidence currently available for the use of subcutaneous trastuzumab in the treatment of gastric cancer. </p><h3><em>Cost and Savings</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in the last three years in New Zealand, there was an average incidence of 640 cases of gastric cancer annually, comprising both stomach cancers and cancers of the lower third of the oesophagus. The Committee considered approximately 65% of cases would be of an advanced stage, and of the approximately 400 advanced gastric cancer cases, 80 would be expected to be HER2-positive. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the Pharmac estimate of 1.5 hospitalisations and 0.7 Emergency Department visits per patient per year with gastric cancer, based on the publication by Abraham et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/32996811/"" target=""_blank"">Future Oncol 2021;17: 291-99</a>). The Committee noted that few of the patients in this publication were treated with trastuzumab, and that health resource utilisation would be expected to be lower with trastuzumab, given improved response rates to treatment and better performance status. \xa0 \xa01.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the high cost of treatment when first considered in 2011 and considered that the ongoing competitive process for intravenous trastuzumab is likely to result in a much more favourable cost to the health system. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that those on treatment would be assessed by a specialist every three weeks while on chemotherapy, and if continued on maintenance trastuzumab this would be every three-six weeks. The Committee noted that trastuzumab use would increase the need for cardiac testing in the form of multigated acquisition (MUGA) scan or echocardiogram, which would have to be performed every three months. </p><h3><em>Funding Criteria</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the greatest benefit for trastuzumab in the treatment of gastric cancer is in those with ‘high’ HER2-positivity (ie high expression of HER2 as defined by IHC2+/FISH+ or IHC3+) and considered it appropriate to restrict trastuzumab treatment to those with high expression. The Committee noted that HER2 expression testing varies across centres and considered that due to the intra-tumoral heterogeneity of these cancers, multiple biopsies are needed to ensure sufficient tissue is collected. The Committee noted that many biopsy specimens are found to be necrotic in nature or don’t contain tumour and considered that these can be used as negative controls. The Committee noted that there is currently no formal consensus relating to the number of endoscopic biopsies required for HER2 testing, with international guidance ranging from four to eight. </p><h3><em>Summary for Assessment</em></h3><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for trastuzumab if it were to be funded in New Zealand for locally advanced or metastatic gastric cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. \xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000qywP&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lDIM"" alt=""image.png""></img></p>', 'fs': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding trastuzumab for the treatment of gastric cancer on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experience a significantly higher rate of stomach cancer than non-Māori<span style=""font-size: 10pt;""> </span>and that Māori also experience a significantly higher mortality rate from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a><u>). </u></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for trastuzumab for the treatment of HER2-positive gastric cancer was reviewed by <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"">PTAC</a> (recommended for funding with a low priority) and the <a href=""https://pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf"" target=""_blank"">Cancer Treatments Advisory Committee</a> (at the time “CaTSoP”, recommended for decline) in 2011. The Committee noted that, in 2011, the clinical relevance of the survival benefits seen in the pivotal ToGa trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/20728210/"" target=""_blank"">Bang et al. Lancet. 2010;376:687-97</a>) were unclear. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that since 2011, more evidence has become available for the use of trastuzumab in the treatment of gastric cancer. The Committee also noted that, at a CTAC meeting in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, the Committee supported a competitive process for the supply of trastuzumab, and considered that further assessment of the use of trastuzumab in gastric cancer was warranted.</p><h3><em>Health Need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to the <a href=""https://www.health.govt.nz/publication/new-cancer-registrations-2018"" target=""_blank"">2018 new cancer registration data from the Ministry of Health</a> (Manatū Hauora), stomach cancer occurs at a rate of 5.3 per 100,000 in New Zealand, with the total number of registrations at 408 for that year. The Committee also noted that mortality data from 2017 indicates that 288 New Zealanders died from stomach cancer that year, 47 of which were Māori. The Committee also noted that a further 90 New Zealanders likely died from cancer of the gastro-oesophageal junction in that year. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to Ministry of Health New Zealand Cancer Registry data, in 2021 85 of the total 500 stomach cancer registrations were Māori, and 48 were of Pacific ethnicity. The Committee noted that data from Qlik also reports that, for “lower third oesophageal cancer registrations”, 19 registrations out of a total of 183 were for individuals who were of Māori ethnicity and 3 were of Pacific ethnicity. The Committee considered that it was reasonable to assume that all cancer registrations for the lower third of the oesophagus would be considered part of the gastro-oesophageal junction and therefore eligible for treatment with trastuzumab. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that globally the vast majority of gastric cancers are adenocarcinomas, which can be further subdivided into intestinal and diffuse type, with intestinal-type gastric cancer being more common in older individuals and more strongly associated with exposure to environmental risk factors. The Committee noted that diffuse-type gastric cancer is more associated with an earlier onset and a family history of the disease. The Committee also noted that HER2-positivity is predominantly seen in intestinal type gastric cancer, with a low prevalence in diffuse type gastric cancer (32% vs. 6%; <a href=""https://pubmed.ncbi.nlm.nih.gov/18441328/"" target=""_blank"">Gravalos C. Jimeno A. Ann Oncol. 2008;19:1523-9</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Although the rate of stomach cancer for both Māori and non-Māori has nearly halved over the last 20 years, the Committee noted that compared with non-Māori, Māori experience significantly higher rates of both stomach cancer incidence and mortality from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a>). The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pacific peoples also experience higher rates of both incidence and mortality in relation stomach cancer compared with New Zealand Europeans. The Committee noted that in addition to genetic factors, Māori and Pacific peoples’ have an increased exposure to environmental risk factors for gastric cancer, and their health outcomes from gastric cancer are further compromised by the late stage of the cancer at diagnosis, limited access to endoscopy services outside of main centres.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the initial symptoms of gastric cancer are often non-specific, and that progressive gastric cancers lead to nutritional decline, difficulty swallowing, and a rapidly declining performance status. The Committee also noted that gastric cancer is associated with a high level of carer burden. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that currently, treatment options for gastric cancer in New Zealand are limited, with those affected generally receiving doublet chemotherapy, with response rates at about 50%, and a duration of response limited to six-nine months. The Committee noted that generally individuals are usually only able to be treated with one line of treatment and/or palliative care. The Committee noted that in New Zealand treatment would be either Xelox (capecitabine and oxaliplatin) or FOLFOX (folinic acid, fluorouracil, and oxaliplatin). The Committee considered that use of triplet chemotherapy is generally rare (owing to increased toxicity with marginal incremental benefit), and that very few would have triplet chemotherapy in New Zealand.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that internationally, treatment of gastric cancer is often driven by biomarker status (eg HER-2, dMMR +/-, PD-L1 status). </p><h3><em>Health Benefit</em></h3><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that trastuzumab is a monoclonal antibody that targets the HER2 receptor, inducing antibody-dependent cellular cytotoxicity, inhibiting HER2-mediated signalling, and preventing cleavage of the extracellular domain of HER2. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted again the primary trial for trastuzumab in combination with chemotherapy compared with chemotherapy alone in the treatment of gastric cancer (ToGa trial) which recruited 594 patients with inoperable, locally advanced, recurrent, and/or metastatic HER2-positive cancer of the stomach or the gastro-oesophageal junction. The Committee noted that the median overall survival for the total trial population was 13.8 months with trastuzumab compared to 11.1 months for those treated with chemotherapy alone (hazard ratio [HR] 0.74; 95% CI 0.60 to 0.91; p=0.0046). The Committee noted that for patients with high HER2 expression (IHC 2+ and FISH-positive tumours or IHC 3+ tumours) the median overall survival was 16.0 months with trastuzumab treatment, versus 11.8 months with chemotherapy alone (HR 0.65; 95% CI 0.51 to 0.83). The Committee noted that the benefit of trastuzumab treatment is greater for patients with higher HER2 expression, with the greatest benefit seen in those with IHC 3+/FISH positive patients. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the addition of trastuzumab to cisplatin and 5FU-based therapy increased response rates from 35% to 47%. The Committee also noted that the toxicities were similar between treatment arms, with a minor increase in grade 3-4 diarrhoea and asymptomatic reduction in left ventricular ejection fraction with trastuzumab. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the following additional evidence for the use of trastuzumab in the treatment of gastric cancer: </p><p class=""ql-indent-1"">1.16.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26857702/"" target=""_blank"">Gong et al. MBC Cancer. 2016;16:68</a> CGOG 1001: an open-label, multicenter, prospective phase II study (n=51) of trastuzumab in combination of oxaliplatin and capecitabine in which 66.5%of participants responded to treatment. </p><p class=""ql-indent-1"">1.16.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784321/pdf/nihms-1051900.pdf"" target=""_blank"">Mondaca et al. Gastric Cancer. 2019;22:355-62</a>: a single-arm multicentre phase II study (n=26) of trastuzumab in combination with docetaxel and 5-flurouracil in which the objective response rate was 65%, and the toxicity profile was high. </p><p class=""ql-indent-1"">1.16.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30927036/"" target=""_blank"">Rivera et al. Cancer Chemother Pharmacol. 2019;83:1175-81</a> HERXO: a multicentre, prospective, non-randomised, non-controlled, open-label national (Spanish) phase II study (n=45) of trastuzumab in combination with oxaliplatin and capecitabine which reported a 46.7% response rate. </p><p class=""ql-indent-1"">1.16.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31768696/"" target=""_blank"">Yuki et al. Cancer Chemother Pharmacol. 2020;85:217-23</a> SOX: a multicentre, open-label, single arm, phase II trial (n=39) of trastuzumab in combination with oxaliplatin and S-1 which reported an 82.1% response rate. </p><p class=""ql-indent-1"">1.16.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31102009/"" target=""_blank"">Takahari et al. Gastric Cancer. 2019;22:1238-46</a>: a multicentre, prospective, single-arm phase II study (n=75) of trastuzumab in combination with oxaliplatin and S-1 which reported an objective response rate of 70.7%. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted a meta-analysis comparing the chemotherapy backbones for first-line trastuzumab treatment-containing regimens for HER2-postive advanced oesophagogastric cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/29451302/"" target=""_blank"">Ter Veer et al. Int J Cancer. 2018;143:438-48</a>) which reported an overall survival advantage with oxaliplatin versus cisplatin (20.7 months versus 16 months, respectively; HR 0.75). The Committee noted that oxaliplatin regimens are also less toxic than cisplatin regimens. The Committee considered that the difference in overall survival in the meta-analysis compared to the ToGa trial is likely due to the improvement in best supportive care since publication of the ToGa trial. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence indicates an advantage for an oxaliplatin doublet, such as Xelox or FLOFOX, rather than the ToGa regimen of cisplatin with 5-FU. The Committee considered that triplet regimens show no additional survival benefit and have worse toxicity profiles. </p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that if trastuzumab were to be funded in this setting, there would be a slight decrease in demand on family support and palliative care services. The Committee considered that those who progress following treatment with a trastuzumab containing regimen in the first line, would then be treated with a taxane chemotherapy. </p><h3><em>Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that use of trastuzumab in this setting would add an additional 30 minutes to an already prolonged chemotherapy administration regimen but considered that this would not impact the number of people with gastric cancer receiving treatment in this setting. The Committee noted that there was no evidence currently available for the use of subcutaneous trastuzumab in the treatment of gastric cancer. </p><h3><em>Cost and Savings</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in the last three years in New Zealand, there was an average incidence of 640 cases of gastric cancer annually, comprising both stomach cancers and cancers of the lower third of the oesophagus. The Committee considered approximately 65% of cases would be of an advanced stage, and of the approximately 400 advanced gastric cancer cases, 80 would be expected to be HER2-positive. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the Pharmac estimate of 1.5 hospitalisations and 0.7 Emergency Department visits per patient per year with gastric cancer, based on the publication by Abraham et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/32996811/"" target=""_blank"">Future Oncol 2021;17: 291-99</a>). The Committee noted that few of the patients in this publication were treated with trastuzumab, and that health resource utilisation would be expected to be lower with trastuzumab, given improved response rates to treatment and better performance status. \xa0 \xa01.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the high cost of treatment when first considered in 2011 and considered that the ongoing competitive process for intravenous trastuzumab is likely to result in a much more favourable cost to the health system. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that those on treatment would be assessed by a specialist every three weeks while on chemotherapy, and if continued on maintenance trastuzumab this would be every three-six weeks. The Committee noted that trastuzumab use would increase the need for cardiac testing in the form of multigated acquisition (MUGA) scan or echocardiogram, which would have to be performed every three months. </p><h3><em>Funding Criteria</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the greatest benefit for trastuzumab in the treatment of gastric cancer is in those with ‘high’ HER2-positivity (ie high expression of HER2 as defined by IHC2+/FISH+ or IHC3+) and considered it appropriate to restrict trastuzumab treatment to those with high expression. The Committee noted that HER2 expression testing varies across centres and considered that due to the intra-tumoral heterogeneity of these cancers, multiple biopsies are needed to ensure sufficient tissue is collected. The Committee noted that many biopsy specimens are found to be necrotic in nature or don’t contain tumour and considered that these can be used as negative controls. The Committee noted that there is currently no formal consensus relating to the number of endoscopic biopsies required for HER2 testing, with international guidance ranging from four to eight. </p><h3><em>Summary for Assessment</em></h3><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for trastuzumab if it were to be funded in New Zealand for locally advanced or metastatic gastric cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. \xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000qywP&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lDIM"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for trastuzumab for the treatment of locally advanced or metastatic gastric cancer. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for trastuzumab for the treatment of locally advanced or metastatic gastric cancer. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywP2AQ'}, 'Id': 'a0POZ000000qywP2AQ', 'Event_Date__c': '2023-05-22', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'May 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that trastuzumab for the treatment of locally advanced or metastatic gastric cancer be listed with a <strong>high priority</strong> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application</strong><span style=""font-size: 9pt;""> — (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for application meeting the following criteria: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has locally advanced or metastatic gastric cancer expressing HER-2 IHC 2+FISH+ or IHC3+; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG score of 0-2.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">— (locally advanced or metastatic gastric cancer) only from a relevant specialist or relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2)</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Trastuzumab to be discontinued at disease progression.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Advisory Committee noted the high health needs relating to the significant symptom burden and modest survival from gastric cancer, the apparent survival advantage from treatment with trastuzumab and likely reduced health resource usage, and the significant cost impact of use of biosimilar trastuzumab in this indication, and the likely reduction in price of trastuzumab following the current competitive process.\xa0</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for trastuzumab for the treatment of locally advanced or metastatic gastric cancer. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em>Māori Impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding trastuzumab for the treatment of gastric cancer on Māori health areas of focus and Māori health outcomes. The Committee noted that Māori experience a significantly higher rate of stomach cancer than non-Māori<span style=""font-size: 10pt;""> </span>and that Māori also experience a significantly higher mortality rate from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a><u>). </u></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for trastuzumab for the treatment of HER2-positive gastric cancer was reviewed by <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"">PTAC</a> (recommended for funding with a low priority) and the <a href=""https://pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2011-04.pdf"" target=""_blank"">Cancer Treatments Advisory Committee</a> (at the time “CaTSoP”, recommended for decline) in 2011. The Committee noted that, in 2011, the clinical relevance of the survival benefits seen in the pivotal ToGa trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/20728210/"" target=""_blank"">Bang et al. Lancet. 2010;376:687-97</a>) were unclear. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that since 2011, more evidence has become available for the use of trastuzumab in the treatment of gastric cancer. The Committee also noted that, at a CTAC meeting in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, the Committee supported a competitive process for the supply of trastuzumab, and considered that further assessment of the use of trastuzumab in gastric cancer was warranted.</p><h3><em>Health Need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to the <a href=""https://www.health.govt.nz/publication/new-cancer-registrations-2018"" target=""_blank"">2018 new cancer registration data from the Ministry of Health</a> (Manatū Hauora), stomach cancer occurs at a rate of 5.3 per 100,000 in New Zealand, with the total number of registrations at 408 for that year. The Committee also noted that mortality data from 2017 indicates that 288 New Zealanders died from stomach cancer that year, 47 of which were Māori. The Committee also noted that a further 90 New Zealanders likely died from cancer of the gastro-oesophageal junction in that year. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that according to Ministry of Health New Zealand Cancer Registry data, in 2021 85 of the total 500 stomach cancer registrations were Māori, and 48 were of Pacific ethnicity. The Committee noted that data from Qlik also reports that, for “lower third oesophageal cancer registrations”, 19 registrations out of a total of 183 were for individuals who were of Māori ethnicity and 3 were of Pacific ethnicity. The Committee considered that it was reasonable to assume that all cancer registrations for the lower third of the oesophagus would be considered part of the gastro-oesophageal junction and therefore eligible for treatment with trastuzumab. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that globally the vast majority of gastric cancers are adenocarcinomas, which can be further subdivided into intestinal and diffuse type, with intestinal-type gastric cancer being more common in older individuals and more strongly associated with exposure to environmental risk factors. The Committee noted that diffuse-type gastric cancer is more associated with an earlier onset and a family history of the disease. The Committee also noted that HER2-positivity is predominantly seen in intestinal type gastric cancer, with a low prevalence in diffuse type gastric cancer (32% vs. 6%; <a href=""https://pubmed.ncbi.nlm.nih.gov/18441328/"" target=""_blank"">Gravalos C. Jimeno A. Ann Oncol. 2008;19:1523-9</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Although the rate of stomach cancer for both Māori and non-Māori has nearly halved over the last 20 years, the Committee noted that compared with non-Māori, Māori experience significantly higher rates of both stomach cancer incidence and mortality from stomach cancer compared to non-Māori (<a href=""https://teaho.govt.nz/static/reports/state-of-cancer-in-new-zealand-2020%20(revised%20March%202021).pdf"" target=""_blank"">Te Aho report. 2020</a>). The Committee noted that a study from 2017 reported that approximately half of Māori with stomach cancer had diffuse stomach cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/28732086/"" target=""_blank"">Ellison-Loschmann et al. PLoS One. 2017;12:e0181581</a>), and that BPAC <a href=""https://bpac.org.nz/2018/gastric-cancer.aspx#:~:text=It%20is%20now%20estimated%20that,attributed%20to%20germline%20CDH1%20mutations.&amp;text=The%20incidence%20and%20mortality%20of,non%2DM%C4%81ori%20in%20New%20Zealand."" target=""_blank"">reported in 2018</a> that approximately 13% of advanced diffuse gastric cancers in Māori are hereditary. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pacific peoples also experience higher rates of both incidence and mortality in relation stomach cancer compared with New Zealand Europeans. The Committee noted that in addition to genetic factors, Māori and Pacific peoples’ have an increased exposure to environmental risk factors for gastric cancer, and their health outcomes from gastric cancer are further compromised by the late stage of the cancer at diagnosis, limited access to endoscopy services outside of main centres.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the initial symptoms of gastric cancer are often non-specific, and that progressive gastric cancers lead to nutritional decline, difficulty swallowing, and a rapidly declining performance status. The Committee also noted that gastric cancer is associated with a high level of carer burden. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that currently, treatment options for gastric cancer in New Zealand are limited, with those affected generally receiving doublet chemotherapy, with response rates at about 50%, and a duration of response limited to six-nine months. The Committee noted that generally individuals are usually only able to be treated with one line of treatment and/or palliative care. The Committee noted that in New Zealand treatment would be either Xelox (capecitabine and oxaliplatin) or FOLFOX (folinic acid, fluorouracil, and oxaliplatin). The Committee considered that use of triplet chemotherapy is generally rare (owing to increased toxicity with marginal incremental benefit), and that very few would have triplet chemotherapy in New Zealand.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that internationally, treatment of gastric cancer is often driven by biomarker status (eg HER-2, dMMR +/-, PD-L1 status). </p><h3><em>Health Benefit</em></h3><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that trastuzumab is a monoclonal antibody that targets the HER2 receptor, inducing antibody-dependent cellular cytotoxicity, inhibiting HER2-mediated signalling, and preventing cleavage of the extracellular domain of HER2. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted again the primary trial for trastuzumab in combination with chemotherapy compared with chemotherapy alone in the treatment of gastric cancer (ToGa trial) which recruited 594 patients with inoperable, locally advanced, recurrent, and/or metastatic HER2-positive cancer of the stomach or the gastro-oesophageal junction. The Committee noted that the median overall survival for the total trial population was 13.8 months with trastuzumab compared to 11.1 months for those treated with chemotherapy alone (hazard ratio [HR] 0.74; 95% CI 0.60 to 0.91; p=0.0046). The Committee noted that for patients with high HER2 expression (IHC 2+ and FISH-positive tumours or IHC 3+ tumours) the median overall survival was 16.0 months with trastuzumab treatment, versus 11.8 months with chemotherapy alone (HR 0.65; 95% CI 0.51 to 0.83). The Committee noted that the benefit of trastuzumab treatment is greater for patients with higher HER2 expression, with the greatest benefit seen in those with IHC 3+/FISH positive patients. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the addition of trastuzumab to cisplatin and 5FU-based therapy increased response rates from 35% to 47%. The Committee also noted that the toxicities were similar between treatment arms, with a minor increase in grade 3-4 diarrhoea and asymptomatic reduction in left ventricular ejection fraction with trastuzumab. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the following additional evidence for the use of trastuzumab in the treatment of gastric cancer: </p><p class=""ql-indent-1"">1.16.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26857702/"" target=""_blank"">Gong et al. MBC Cancer. 2016;16:68</a> CGOG 1001: an open-label, multicenter, prospective phase II study (n=51) of trastuzumab in combination of oxaliplatin and capecitabine in which 66.5%of participants responded to treatment. </p><p class=""ql-indent-1"">1.16.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784321/pdf/nihms-1051900.pdf"" target=""_blank"">Mondaca et al. Gastric Cancer. 2019;22:355-62</a>: a single-arm multicentre phase II study (n=26) of trastuzumab in combination with docetaxel and 5-flurouracil in which the objective response rate was 65%, and the toxicity profile was high. </p><p class=""ql-indent-1"">1.16.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30927036/"" target=""_blank"">Rivera et al. Cancer Chemother Pharmacol. 2019;83:1175-81</a> HERXO: a multicentre, prospective, non-randomised, non-controlled, open-label national (Spanish) phase II study (n=45) of trastuzumab in combination with oxaliplatin and capecitabine which reported a 46.7% response rate. </p><p class=""ql-indent-1"">1.16.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31768696/"" target=""_blank"">Yuki et al. Cancer Chemother Pharmacol. 2020;85:217-23</a> SOX: a multicentre, open-label, single arm, phase II trial (n=39) of trastuzumab in combination with oxaliplatin and S-1 which reported an 82.1% response rate. </p><p class=""ql-indent-1"">1.16.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31102009/"" target=""_blank"">Takahari et al. Gastric Cancer. 2019;22:1238-46</a>: a multicentre, prospective, single-arm phase II study (n=75) of trastuzumab in combination with oxaliplatin and S-1 which reported an objective response rate of 70.7%. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted a meta-analysis comparing the chemotherapy backbones for first-line trastuzumab treatment-containing regimens for HER2-postive advanced oesophagogastric cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/29451302/"" target=""_blank"">Ter Veer et al. Int J Cancer. 2018;143:438-48</a>) which reported an overall survival advantage with oxaliplatin versus cisplatin (20.7 months versus 16 months, respectively; HR 0.75). The Committee noted that oxaliplatin regimens are also less toxic than cisplatin regimens. The Committee considered that the difference in overall survival in the meta-analysis compared to the ToGa trial is likely due to the improvement in best supportive care since publication of the ToGa trial. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence indicates an advantage for an oxaliplatin doublet, such as Xelox or FLOFOX, rather than the ToGa regimen of cisplatin with 5-FU. The Committee considered that triplet regimens show no additional survival benefit and have worse toxicity profiles. </p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that if trastuzumab were to be funded in this setting, there would be a slight decrease in demand on family support and palliative care services. The Committee considered that those who progress following treatment with a trastuzumab containing regimen in the first line, would then be treated with a taxane chemotherapy. </p><h3><em>Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that use of trastuzumab in this setting would add an additional 30 minutes to an already prolonged chemotherapy administration regimen but considered that this would not impact the number of people with gastric cancer receiving treatment in this setting. The Committee noted that there was no evidence currently available for the use of subcutaneous trastuzumab in the treatment of gastric cancer. </p><h3><em>Cost and Savings</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that in the last three years in New Zealand, there was an average incidence of 640 cases of gastric cancer annually, comprising both stomach cancers and cancers of the lower third of the oesophagus. The Committee considered approximately 65% of cases would be of an advanced stage, and of the approximately 400 advanced gastric cancer cases, 80 would be expected to be HER2-positive. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the Pharmac estimate of 1.5 hospitalisations and 0.7 Emergency Department visits per patient per year with gastric cancer, based on the publication by Abraham et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/32996811/"" target=""_blank"">Future Oncol 2021;17: 291-99</a>). The Committee noted that few of the patients in this publication were treated with trastuzumab, and that health resource utilisation would be expected to be lower with trastuzumab, given improved response rates to treatment and better performance status. \xa0 \xa01.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the high cost of treatment when first considered in 2011 and considered that the ongoing competitive process for intravenous trastuzumab is likely to result in a much more favourable cost to the health system. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that those on treatment would be assessed by a specialist every three weeks while on chemotherapy, and if continued on maintenance trastuzumab this would be every three-six weeks. The Committee noted that trastuzumab use would increase the need for cardiac testing in the form of multigated acquisition (MUGA) scan or echocardiogram, which would have to be performed every three months. </p><h3><em>Funding Criteria</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the greatest benefit for trastuzumab in the treatment of gastric cancer is in those with ‘high’ HER2-positivity (ie high expression of HER2 as defined by IHC2+/FISH+ or IHC3+) and considered it appropriate to restrict trastuzumab treatment to those with high expression. The Committee noted that HER2 expression testing varies across centres and considered that due to the intra-tumoral heterogeneity of these cancers, multiple biopsies are needed to ensure sufficient tissue is collected. The Committee noted that many biopsy specimens are found to be necrotic in nature or don’t contain tumour and considered that these can be used as negative controls. The Committee noted that there is currently no formal consensus relating to the number of endoscopic biopsies required for HER2 testing, with international guidance ranging from four to eight. </p><h3><em>Summary for Assessment</em></h3><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for trastuzumab if it were to be funded in New Zealand for locally advanced or metastatic gastric cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. \xa0</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000qywP&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lDIM"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000EDzaQAG'}, 'change': None}]",Dec 2010,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2023', 'fs': 'Jan 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywN2AQ'}, 'Id': 'a0POZ000000qywN2AQ', 'Event_Date__c': '2023-01-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2023', 'Status_History__c': 'a132P000000EDJBQA4'}, 'change': None}]",Jan 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywI2AQ'}, 'Id': 'a0POZ000000qywI2AQ', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqWOQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2023', 'fs': 'Jan 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywO2AQ'}, 'Id': 'a0POZ000000qywO2AQ', 'Event_Date__c': '2023-01-25', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jan 2023', 'Status_History__c': 'a132P000000EE0NQAW'}, 'change': None}]",Nov 2013,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><span style=""color: rgb(68, 68, 68);"">Proposal to decline inactive applications - To help make our decision-making process clearer, we are seeking feedback on a proposal for PHARMAC to make decisions to decline funding applications for 8 medicines.</span></p>', 'fs': '<p><span style=""color: rgb(68, 68, 68);"">Proposal to decline inactive applications - To help make our decision-making process clearer, we are seeking feedback on a proposal for PHARMAC to make decisions to decline funding applications for 8 medicines.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2019', 'fs': 'Apr 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywJ2AQ'}, 'Id': 'a0POZ000000qywJ2AQ', 'Event_Date__c': '2019-04-30', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications/"" target=""_blank"">Consultation letter</a></p>', 'Summary__c': '<p><span style=""color: rgb(68, 68, 68);"">Proposal to decline inactive applications - To help make our decision-making process clearer, we are seeking feedback on a proposal for PHARMAC to make decisions to decline funding applications for 8 medicines.</span></p>', 'Formatted_Date__c': 'Apr 2019', 'Status_History__c': 'a132P000000ArepQAC'}, 'change': None}, {'Summary': {'s': '<p><span style=""color: rgb(68, 68, 68);"">We are seeking feedback on a proposal to widen funded access to intravenous trastuzumab to include gastric cancer, as part of a transition to a biosimilar brand of intravenous trastuzumab. Feedback can be submitted to </span><a href=""mailto:consult@pharmac.govt.nz"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">consult@pharmac.govt.nz</a><span style=""color: rgb(68, 68, 68);""> until 4 pm, 30 June 2023.</span></p>', 'fs': '<p><span style=""color: rgb(68, 68, 68);"">We are seeking feedback on a proposal to widen funded access to intravenous trastuzumab to include gastric cancer, as part of a transition to a biosimilar brand of intravenous trastuzumab. Feedback can be submitted to </span><a href=""mailto:consult@pharmac.govt.nz"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">consult@pharmac.govt.nz</a><span style=""color: rgb(68, 68, 68);""> until 4 pm, 30 June 2023.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-06-08-proposal-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-06-08-proposal-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywQ2AQ'}, 'Id': 'a0POZ000000qywQ2AQ', 'Event_Date__c': '2023-06-08', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-06-08-proposal-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand"" target=""_blank"">Consultation letter</a></p>', 'Summary__c': '<p><span style=""color: rgb(68, 68, 68);"">We are seeking feedback on a proposal to widen funded access to intravenous trastuzumab to include gastric cancer, as part of a transition to a biosimilar brand of intravenous trastuzumab. Feedback can be submitted to </span><a href=""mailto:consult@pharmac.govt.nz"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">consult@pharmac.govt.nz</a><span style=""color: rgb(68, 68, 68);""> until 4 pm, 30 June 2023.</span></p>', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EJECQA4'}, 'change': None}]",Apr 2019,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywK2AQ'}, 'Id': 'a0POZ000000qywK2AQ', 'Event_Date__c': '2019-05-21', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000ArffQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywR2AQ'}, 'Id': 'a0POZ000000qywR2AQ', 'Event_Date__c': '2023-07-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000EwKSQA0'}, 'change': None}]",May 2019,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p>This application was originally declined in 2019. You can <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-medicines-funding-applications/"" target=""_blank"">read about this decision here.</a></p><p><br></p><p>We reassessed the application after feedback from consumer groups and healthcare professionals. Access will now be widened from 1 December 2023.</p>', 'fs': '<p>This application was originally declined in 2019. You can <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-medicines-funding-applications/"" target=""_blank"">read about this decision here.</a></p><p><br></p><p>We reassessed the application after feedback from consumer groups and healthcare professionals. Access will now be widened from 1 December 2023.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/23-08-23-decision-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/23-08-23-decision-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000qywS2AQ'}, 'Id': 'a0POZ000000qywS2AQ', 'Event_Date__c': '2023-08-23', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/23-08-23-decision-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand/"" target=""_blank"">Notification letter</a></p>', 'Summary__c': '<p>This application was originally declined in 2019. You can <a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-medicines-funding-applications/"" target=""_blank"">read about this decision here.</a></p><p><br></p><p>We reassessed the application after feedback from consumer groups and healthcare professionals. Access will now be widened from 1 December 2023.</p>', 'Formatted_Date__c': 'Aug 2023', 'Status_History__c': 'a13OZ000001bicbYAA'}, 'change': None}]",Aug 2023,False,True
